Imatinib mesylate-induced pseudoporphyria

Journal of the American Academy of Dermatology

Volumn 63, Issue 1, 2010, Pages

  Berghoff, Adar T ^a   English III, Joseph C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; IMATINIB; NAPROXEN;

ADULT; ARTICLE; BLISTER; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOFLUORESCENCE; ORAL BLISTER; PATIENT REFERRAL; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; PSEUDOPORPHYRIA; SKIN FRAGILITY; TREATMENT WITHDRAWAL;

ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PIPERAZINES; PORPHYRIA CUTANEA TARDA; PYRIMIDINES;

EID: 77953239768     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.01.060     Document Type: Article

References (6)

1. Timmer-de Mik L., Kardaun S.H., Kramer M.H., Hayes D.P., and Bousema M.T. Imatinib-induced pseudoporphyria. Clin Exp Dermatol 34 (2009) 705-707
2. Green J.J., and Manders S.M. Pseudoporphyria. J Am Acad Dermatol 44 (2001) 100-108
3. Girshick H.J., Hamm H., Ganser G., and Huppertz H.I. Naproxen-induced pseudoporphyria: appearance of new skin lesions after discontinuation of treatment. Scand J Rheumatol 24 (1995) 108-111
4. Duffaud F., and Le Cesne A. Imatinib in the treatment of solid tumours. Target Oncol 4 (2009) 45-56
5. Heidary N., Naik H., and Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 58 (2008) 545-570
6. Breccia M., Latagliata R., Carmosino I., Mandelli F., and Alimena G. Reactivation of porphyria cutanea tarda as a possible side effect of imatinib at high dosage in chronic myeloid leukemia. Leukemia 18 (2004) 182